Uncategorized

Mirum Pharmaceuticals, Inc. announced that on January 10, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 50,950 shares of common stock and 25,480 restricted stock units to seven new employees under Mirum’s 2020 Inducement Plan.

Ascentage Pharma announced that Dr. Dajun Yang, the company’s Chairman and CEO, gave a speech at the 42nd Annual J.P. Morgan Healthcare Conference.

HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the New Drug Application (“NDA”) for sovleplenib for the treatment of adult patients with primary immune thrombocytopenia (“ITP”) has been accepted for review and granted priority review by the China National Medical Products Administration (“NMPA”).

The BioSpace team is recording from San Francisco as they bring you the the latest highlights from Day 3 at JPM2024.

Gilead’s stock traded lower on news that claims will proceed that allege the company delayed the development of newer, safer HIV drugs in order to maximize profits.

For experts on Boston Consulting Group’s generative AI panel at the Biotech Showcase, effectively using the technology in the biotech industry will be a collaborative process.

Kentucky-based Baptist Health has gone out of network with UnitedHealthcare and Centene’s WellCare Medicare Advantage plans after failing to agree to contract terms.

The job cuts affect roles across corporate, sales and marketing, and operations.

Stifel analysts expressed support for the decision, predicting it will benefit revenue growth and profitability, and increase focus.

Raju Iyer will be responsible for the California-based health system’s financial planning. He replaces Dominic Nakis, who served as interim CFO.